Cytokinetics Incorporated has announced that the Committee for Medicinal Products for Human Use $(CHMP)$ of the European Medicines Agency $(EMA)$ has issued a positive opinion recommending marketing authorization for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. A final decision from the European Commission is expected in the first quarter of 2026. Additionally, aficamten is under regulatory review in the U.S. by the FDA, with a target action date of December 26, 2025, and is also being reviewed by the Center for Drug Evaluation $(CDE)$ of the China National Medical Products Administration (NMPA) with Priority Review status.